SanBio Company Limited
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/03/17 | ¥-20.69 | ¥-14.80 | +28.5% |
| 2025/12/15 | ¥-15.35 | ¥-9.95 | +35.2% |
| 2018/12/14 | ¥-16.10 | ¥-10.18 | +36.8% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
iShares Trust-iShares Core MSCI EAFE ETF
|
452.5K | +13.95% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
237.8K | -0.34% | |
|
SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E
|
187.5K | 0.00% | |
|
College Retirement Equities Fd.-College Retirement Equities Fd. - Tota
|
174.9K | +3.25% | |
|
iShares Trust-iShares Core MSCI International Developed Markets ETF
|
85.7K | +18.53% | |
|
TIAA-CREF Funds-Nuveen Quant International Small Cap Equity Fund
|
67.7K | -4.11% |
Financial Performance
2026/08/23 UpdatedNo financial data available
Latest IR Information
-
【SanBio】Regenerative Medicine Drug Approval and Research & Development Progress｜June 2026
SanBio recorded research and development expenses of 680 million yen in the first quarter of the fiscal year ending January 2027, with an operating loss of 953 million yen and a net loss of 836 million yen. The company is...
Read more -
【SanBio】Notice of Non-Operating Income and Corporate Tax Adjustment for Q1 FY2026｜June 15, 2026
SanBio announced that it recorded foreign exchange gains of 177 million yen and a corporate tax adjustment of 55 million yen in the first quarter of the fiscal year ending January 2027, impacting its performance.
Read more -
【Sambio】Reimbursement Listing and Future Developments of Akugo Brain Transplant Injection｜May 2026
Sambio officially secured reimbursement listing for Akugo🄬 Brain Transplant Injection on May 20, 2026, and is promoting clinical trials and global expansion. It obtained manufacturing and sales approval in July 2024 and plans to begin initial shipments from August 2026.
Read more -
Approval of Akugo Drug Price by Central Social Insurance Medical Council | May 13, 2026
Samba Bio has received approval for the drug price of Akugo by the Central Social Insurance Medical Council and has revised its consolidated earnings forecast for the January 2027 period. The drug price is set at 72,716,528 yen, and plans...
Read more -
Matters Concerning Business Plan and Growth Potential
SanBio Inc. presented a business plan aiming to become a global leader in brain regeneration by pioneering the world’s first brain regenerative medicine, Akougo®.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,580
Rating Score: 2.60 (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
